CD274 and cervical carcinoma: In addition to the aforementioned drugs, checkpoint inhibitors such as pembrolizumab or cemiplimab are being studied intensively for the treatment of cervical carcinoma, with benefits in PD-L1-positive patients (KEYNOTE 158, KEYNOTE 826) [72,73,74,75].